How Does Regeneron Pharmaceuticals Make its Money?
Regeneron Pharmaceuticals is a leading biotechnology company known for its innovative discovery and development of medicines for serious diseases. The company’s flagship product Dupixent (for eczema, asthma, and other inflammatory conditions) has become one of the best-selling drugs in the world. Regeneron also developed EYLEA for eye diseases and made headlines during COVID-19 with its REGEN-COV antibody cocktail. Founded by scientist-entrepreneurs, Regeneron is widely regarded as having one of the most productive R&D operations in the pharma industry.
Regeneron Pharmaceuticals (REGN) Business Model
Regeneron Pharmaceuticals operates in the biotechnology sector. Below is a summary of Regeneron Pharmaceuticals’ revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Regeneron Pharmaceuticals’ 2024 fiscal year filings with the SEC.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Regeneron Pharmaceuticals Competitors
Regeneron Pharmaceuticals’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Novo Nordisk, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Regeneron Pharmaceuticals stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Dupixent Net Product Sales | $9,100 | $7,400 | +23.0% |
| EYLEA (including HD) | $5,800 | $5,900 | -1.7% |
| Kevzara, Praluent, Libtayo & Other | $1,200 | $1,000 | +20.0% |
| Collaboration Revenue (Sanofi, Bayer) | $2,400 | $2,500 | -4.0% |
| Total Revenue | $14,200 | $13,000 | +9.2% |
Dupixent Net Product Sales — 64% of Revenue
EYLEA (including HD) — 41% of Revenue
Kevzara, Praluent, Libtayo & Other — 8% of Revenue
Collaboration Revenue (Sanofi, Bayer) — 17% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $14,200 | $13,000 |
| Cost of Revenue | $2,200 | $2,100 |
| Gross Profit | $12,000 | $10,900 |
| Operating Expenses | $6,200 | $5,700 |
| Operating Income | $5,800 | $5,200 |
| Net Income | $4,800 | $4,400 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 84.5%
- Operating Margin: 40.8%
- Revenue Growth: 9.2%
Is Regeneron Pharmaceuticals Profitable?
Yes, Regeneron Pharmaceuticals is profitable. The company reported net income of $4,800 on total revenue of $14,200. With an operating margin of 40.8%, Regeneron Pharmaceuticals demonstrates solid profitability for the biotechnology sector. The gross margin of 84.5% reflects Regeneron Pharmaceuticals’ pricing power and cost structure.
What to Watch
- Dupixent label expansion into COPD, food allergy, and other inflammatory conditions
- EYLEA HD uptake amid biosimilar competition for original EYLEA
- Pipeline progress on next-generation obesity and inflammatory drugs
- Sanofi partnership dynamics on Dupixent profit-sharing and eventual transfer
Regeneron Pharmaceuticals (REGN) Financial Summary
Regeneron Pharmaceuticals (REGN) is a biotechnology company that generated $14,200 in total revenue in fiscal year 2024. Revenue grew 9.2% year-over-year. The company earned $4,800 in net income, making it profitable. For a deeper look at Regeneron Pharmaceuticals’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.